Monday, August 19, 2024 5:03:42 PM
Huge started tanking wayyyy before Cellynu was ever in the picture. You must be relatively new to Huge. They can try to whitewash all they want with a name change. Raza, Anthony, Saeed, all pigs at the trough pointing at and blaming one another all growing fat as retail starve. It's all there, ignore the hype and look at the facts. Over the years money has always gone into their pockets and promotions along with awarding themselves massive bonuses. If they truly intended to build true shareholder value more money would go into R&D instead of paid promotions and their pockets. Look at the amounts for paid promotions and salaries over the years then look at the total amount spent on R&D. They spend substantially more on promotions to hype and push paper than they do on R&D to actually build the company.
Bearish
Recent QNTM News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/02/2026 12:30:03 PM
- Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied • GlobeNewswire Inc. • 04/02/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/01/2026 12:02:04 PM
- Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis • GlobeNewswire Inc. • 04/01/2026 12:02:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 11:50:09 AM
- Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis • GlobeNewswire Inc. • 03/30/2026 11:50:00 AM
- Quantum Biopharma Provides Corporate Update • GlobeNewswire Inc. • 03/27/2026 11:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/27/2026 12:10:03 PM
- Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status • GlobeNewswire Inc. • 03/27/2026 12:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/26/2026 12:00:10 PM
- Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis • GlobeNewswire Inc. • 03/26/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/23/2026 12:24:03 PM
- Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd • GlobeNewswire Inc. • 03/23/2026 12:24:00 PM
- Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering • GlobeNewswire Inc. • 03/20/2026 11:35:00 PM
- Quantum BioPharma Provides Corporate Update • GlobeNewswire Inc. • 03/11/2026 11:55:00 PM
- Quantum BioPharma Provides Corporate Update • GlobeNewswire Inc. • 03/10/2026 11:45:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/03/2026 02:19:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/23/2025 01:00:05 PM
- Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) • GlobeNewswire Inc. • 12/23/2025 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2025 09:23:02 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/22/2025 08:48:55 PM
- World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares • ACCESS Newswire • 12/22/2025 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2025 12:00:04 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 12/11/2025 03:14:49 PM
- Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update • Newsfile • 12/11/2025 01:00:00 AM
